Vasopressor and corticosteroid therapy in patients with septic shock

Article Sidebar

PDF
Published: 2023-09-19
DOI: https://doi.org/10.7196/

Main Article Content

A Buckley
Senior Registrar, Department of Pulmonology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

Abstract

-

Downloads

Download data is not yet available.

Article Details

Issue

AJTCCM Vol. 29 No. 3

Section

Breath-Taking News
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited. 

Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository. 

How to Cite

1.
Buckley A. Vasopressor and corticosteroid therapy in patients with septic shock. Afr J Thoracic Crit Care Med [Internet]. 2023 Sep. 19 [cited 2025 Nov. 12];29(3):143. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/1498

References

Teja B, Bosch NA, Walkey AJ. How we escalate vasopressor and corticosteroid therapy in patients with septic shock. Chest 2023163(3):567-574. https://doi.org/10.1016/j.chest.2022.09.019.

McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: A systematic review and meta-analysis. JAMA 2018;319:1889-1900. https://doi.org/10.1001/jama.2018.4528

Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49: e1063–e1143. https://doi.org/10.1097/CCM.0000000000005337

Annane D, Renault A, Brun-Buisson C, et al. CRICS-TRIGGERSEP Network: Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378:809-818. https://doi.org/10.1056/NEJMoa1705716

Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial. JAMA 2020;323:938–949. https://doi.org/10.1001/jama.2020.0930

Tian DH, Smyth C, Keijzers G, Macdonald SP, Peake S, Udy A, Delaney A. Safety of peripheral administration of vasopressor medications: A systematic review. Emerg Med Australas 2020;32(2):220-227. https://doi.org/10.1111/1742-6723.13406